We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

2024 ASPHO/COG Joint Session Evaluation: Pediatric Clinical Cancer Research Collaboration with Europe

1. Name and Credentials (as you would like it to appear on your CME certificate): *This question is required.

2. E-mail Address: *This question is required. This question requires a valid email address.

3. How valuable was the content of this session for you? *This question is required.

4. Learning objectives:

Understand current regulatory requirements in Europe/UK.
Understand the current issues (regulatory requirements, NCI/CTEP requirements, sponsorship, finances, etc.) make trans-Atlantic clinical research/trials challenging.
Understand the pros and cons of current models of trans-Atlantic collaboration for clinical trials/research in pediatric oncology.

Rate your level of agreement with the following statement.

Presenters met stated learning objectives: *This question is required.

5. Speaker Evaluation
Please rate your level of agreement for each speaker on the following:

Presenter was knowledgeable and effective on session's subject matter. *This question is required.

Space Cell	Strongly Agree	Moderately Agree	Neither Agree nor Disagree	Moderately Disagree	Strongly Disagree	N/A
Thomas Gross, MD, PhD	Thomas Gross, MD, PhD: Strongly Agree	Thomas Gross, MD, PhD: Moderately Agree	Thomas Gross, MD, PhD: Neither Agree nor Disagree	Thomas Gross, MD, PhD: Moderately Disagree	Thomas Gross, MD, PhD: Strongly Disagree	Thomas Gross, MD, PhD: N/A
Pamela Kearns, MD	Pamela Kearns, MD: Strongly Agree	Pamela Kearns, MD: Moderately Agree	Pamela Kearns, MD: Neither Agree nor Disagree	Pamela Kearns, MD: Moderately Disagree	Pamela Kearns, MD: Strongly Disagree	Pamela Kearns, MD: N/A
Michel Zwaan, MD, PhD	Michel Zwaan, MD, PhD: Strongly Agree	Michel Zwaan, MD, PhD: Moderately Agree	Michel Zwaan, MD, PhD: Neither Agree nor Disagree	Michel Zwaan, MD, PhD: Moderately Disagree	Michel Zwaan, MD, PhD: Strongly Disagree	Michel Zwaan, MD, PhD: N/A
Cindy L. Schwartz, MD, MPH	Cindy L. Schwartz, MD, MPH: Strongly Agree	Cindy L. Schwartz, MD, MPH: Moderately Agree	Cindy L. Schwartz, MD, MPH: Neither Agree nor Disagree	Cindy L. Schwartz, MD, MPH: Moderately Disagree	Cindy L. Schwartz, MD, MPH: Strongly Disagree	Cindy L. Schwartz, MD, MPH: N/A
Douglas Hawkins, MD	Douglas Hawkins, MD: Strongly Agree	Douglas Hawkins, MD: Moderately Agree	Douglas Hawkins, MD: Neither Agree nor Disagree	Douglas Hawkins, MD: Moderately Disagree	Douglas Hawkins, MD: Strongly Disagree	Douglas Hawkins, MD: N/A

6. The session was scientifically rigorous, balanced, and free of commercial bias.

Explain why:

7. As a result of attending this session, describe one to two changes you intend to make in your practice. *This question is required.

8. Other comments regarding the session: